

FOR IMMEDIATE RELEASE

Contact:

Colleen Hittle

President & CEO

9001 Wesleyan Road Suite, 200

Indianapolis, IN 46268

Ph. (317) 569-9500 x 102

Fax (317) 569-9520

Cell (317) 201-8711

www.ansongroup.com

chittle@ansongroup.com

ANSON GROUP HELPS INNOVATIVE CLIENT ACHIEVE FIRST CONDITIONAL APPROVAL EVER GRANTED FOR A NEW PRESCRIPTION ANIMAL DRUG BY FDA

(INDIANAPOLIS IN) December 30, 2010 – The Anson Group announces today that regulatory consultant Michael R. Langley, DVM, MBA, RAC, has achieved the first FDA approval of a new potentially life-saving prescription drug for dogs using the Conditional Approval regulatory pathway. In obtaining this approval, Dr. Langley and The Anson Group acted as the US Regulatory Agent for AB Science, a French pharmaceutical company which is developing masitinib for multiple indications in human and animal medicine.

On December 15, 2010 the FDA's Center for Veterinary Medicine (CVM) granted Conditional Approval for a new drug, Kinavet CA-1 (masitinib), to treat certain dogs with a type of cancer called mast cell tumors. This is the first new veterinary prescription drug to be approved using the „Conditional Approval“ regulatory mechanism, and it is only the second time that any veterinary drug has been approved by CVM under this mechanism.

“The approval of this novel drug is great news for dogs with this devastating disease and for their owners.” states Dr. Langley. “Dogs with mast cell tumors have only a few alternatives for treatment. Those dogs that fit the indication criteria now have an important new therapeutic option.”

Conditional Approval is a regulatory mechanism established by the US government in 2004 as part of the Minor Use and Minor Species Act. It is intended to encourage development of new drugs for minor species or for diseases that occur infrequently, such as mast cell tumors. Conditional Approval allows CVM to approve a drug based on data showing a „reasonable expectation that the drug will have the effect intended.“ The final data supporting full FDA approval can then be provided later.

The full text of the approved indication is: “For the treatment of recurrent (post-surgery) or nonresectable Grade II or III cutaneous mast cell tumors in dogs that have not previously received radiotherapy and/or chemotherapy except corticosteroids.”

About Anson Group

Headquartered in Carmel Indiana, Anson Group is a minority-owned independent regulatory consulting organization with over 14 years experience as a leading provider of services and

strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group's team of experienced industry experts tailors both enterprise strategies and clearly defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.

About Masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells, important cells for immunity, as well as a limited number of kinases that play key roles in various cancers. Owing to its novel mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases and in certain diseases of the central nervous system. Through its activity of inhibiting certain kinases that are essential in some oncogenic processes, masitinib may have an effect on tumour regression, alone or in combination with chemotherapy. Through its activity on the mast cell and certain kinases essential to the activation of the inflammatory cells and fibrosing tissue remodeling, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. Masitinib, a lead compound, has previously been registered in veterinary medicine in Europe and is pursuing nine phase 3 studies in human medicine, including three studies on-going in pancreatic cancer, GIST and mastocytosis.